SurModics Names David Wood Vice President and General Manager of Its Drug Delivery Business Unit

October 25, 2004 at 4:01 PM EDT

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Oct. 25, 2004--SurModics, Inc. (NASDAQ:SRDX), a leading provider of surface modification and drug delivery solutions to the medical device industry, today announced David S. Wood, 48, will join the company as vice president and general manager of its drug delivery business unit, effective November 1.

Wood has over 24 years experience in the health care industry, most recently as Director of Product Development for the Cardiac Rhythm Management (CRM) division of Guidant Corporation. Prior to Guidant, he served at Eli Lilly and Company in various capacities, including in business development for their medical devices and diagnostics division.

"We are delighted to welcome Dave to our senior management team," said Bruce Barclay, president and chief operating officer. "His extensive management, product development and business development experience in the medical device industry makes him an excellent addition to our company. Dave's strategic thinking and demonstrated ability to lead product development teams will provide great benefit to our customers and insight to SurModics as we continue to exploit the convergence of drugs and devices. "

"I am thrilled to join the SurModics team. SurModics has terrific people, great technologies and is focused on very attractive target markets," Wood said. "It is very exciting to have the opportunity to help the company build on the success of its site specific drug delivery technology. I am convinced that SurModics' technologies will play a significant and expanding role in enhancing products and patient outcomes through the convergence of drugs, medical devices, and biomedical technologies."

Wood graduated cum laude from Vanderbilt University with a bachelor's degree in chemical engineering. He earned his MBA from The Wharton School, University of Pennsylvania.

About SurModics, Inc.

SurModics, Inc., a leading provider of surface modification and drug delivery solutions, licenses its proprietary technologies to medical device, diagnostics, and biotechnology companies around the world. A significant portion of SurModics' revenue is generated through royalties on the sale of coated products. SurModics' Internet address is

CONTACT: SurModics, Inc.
Phil Ankeny, 952-829-2700

SOURCE: SurModics, Inc.